Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
216
resultados
Última actualización
09/10/2025 [12:44:00]
Resultados 100 a 125 de 216
Resumen de: EP4623901A1
Provided is an efficient transdermal delivery system based on an acidic group-containing biomaterial produced by bonding or physically compounding a tertiary amine oxide group-containing polymer to an acidic group-containing biomaterial or an acidic group-containing biomaterial nanogel. The efficient transdermal delivery system does not require a subcutaneous injection. After being smeared or coated on a skin, the transdermal delivery system can effectively penetrate through the stratum corneum of the skin and enter the subcutaneous layers to exert prominent medical aesthetic effects such as wrinkle and fold correction, or to achieve the transdermal delivery of heparin for thrombolysis, or to achieve the delivery of a drug.
Resumen de: MX2025008776A
A composition for treating hyperprocalcitonemia is described. The composition comprises a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and with or without one or more electrolytes, where the amphiphilic emulsifier forms micelles having a lipophilic or hydrophobic core comprising the lipophilic or hydrophobic component in the polar liquid carrier, and /or liposomes organized as a lipid bilayer and/or other particle configurations.
Resumen de: CN120390657A
The present invention relates to compositions for efficient delivery of gene editing agents to target cells, and methods of using the same to treat diseases or conditions.
Resumen de: KR20250142801A
본 발명은 프로비타민 B5기반의 신규한 지질 유도체 화합물과, 이를 포함하는 지질 나노입자 조성물 등에 관한 것이다. 보다 구체적으로는, 신규한 프로비타민 B5 기반의 지질 화합물이 지질 나노입자의 형성에 있어 이온화지질의 역할을 수행하고 안정적인 지질 나노입자를 형성하여 mRNA등의 약학적 유효성분을 체내로 전달하는 데 이용될 수 있다.
Resumen de: KR20250142187A
본 발명은 금속이온과 상호작용이 있는 약물을 사용한 자가조립형 이산화망간 나노약물의 제조 방법에 관한 것으로, 본 발명에 따른 이산화망간 나노약물(Drug/MnO2)은 암세포 및 염증성 세포의 미세환경 조건인 높은 활성산소(Reactive Oxygen Species, ROS, 0.1-1 mM), 낮은 pH(pH 5.5-6.8)에서 분해되어 약물을 방출할 수 있고, 분해 산물인 Mn2+ 이온은 MRI(자기공명영상) T1 조영제로 사용 가능하며, 발생된 산소는 저산소 환경을 개선하여 각종 치료 효율을 증가시킬 수 있다.
Resumen de: AU2024214423A1
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., HSC), and methods of making and using such lipids and targeted lipid. nanoparticles.
Resumen de: KR20250142140A
본 발명은 특정 크기의 나노입자를 유효성분으로 포함하는 장누수증후군 예방, 치료, 또는 개선용 조성물에 관한 것으로서, 본 발명에 따른 특정 크기를 가지는 나노입자는 비스테로이드성 항염제(Nonsteroidal anti-inflammatory drugs, NSAIDs)를 처리하여 장누수증후군을 모사한 세포 및 동물모델에서 장누수로 인해 증가된 장 투과성을 억제 및 감소시킬 수 있다. 또한, 장누수증후군을 동반하는 비알코올성 지방간 질환 동물모델에서 장 투과성을 억제 및 감소시킴에 따라 간기능을 회복하는 효과가 있다. 이에, 본 발명에 따른 특정 크기의 나노입자는 장누수증후군, 비스테로이드성 항염제 치료의 부작용으로 발생하는 장누수증후군, 및 장누수증후군을 동반한 질환의 예방, 치료, 또는 개선용 조성물 등의 제조에 유용하게 이용될 것으로 기대된다.
Resumen de: KR20250142185A
본 발명은 활성성분을 포집한 나노입자(Nanoparticles, NP)와 자가유화 용액(Self-emulsifying solution, SES)으로부터 제조된 자가유화 나노입자(Self-emulsifying nanoparticle, SENP) 및 자가유화 나노입자 운반시스템(Self-emulsifying nanoparticle delivery system, SENPDS)을 제공한다. 경구 투여된 SENPDS는 위장관에서 수성 매체에 희석되면서 형성되는 NP 함유 지질방울은 전신 순환계에 유입되고 체류하면서 활성성분을 지속 방출할 수 있다. 이 과정에서 상기 온전한 NP 함유 지질방울은 자가소수성 반전 및 자가전하 반전을 포함하는 생체장벽 회피 전략으로 활성성분의 생체이용률이 향상됨을 확인하였다. 따라서, 본 발명의 SENPDS는 생체이용률이 향상된 의약품, 건강기능식품 및 화장품을 제공할 수 있다.
Resumen de: WO2025198324A1
The present invention relates to a polymer self-assembly nanocarrier and a method of preparing same, the nanocarrier binding a peptide that targets a specific cell and, simultaneously, carrying an active ingredient that has been verified. The present invention can exhibit various effects such as a moisturizing effect, an increase in filaggrin production, whitening, skin barrier reinforcement and the like by selectively and efficiently delivering a drug through a targeting peptide, can be applied to skin diseases such as atopy or psoriasis, and is expected to enable the maximum effect of an active substance in the pharmaceutical and cosmetic fields to be obtained.
Resumen de: US2025101427A1
In alternative embodiments, provided are methods for eradicating or reducing the in vivo numbers of cancer stem cells comprising administering to an individual in need thereof an ADAR1 (adenosine deaminase associated with RNA1) inhibiting agent, wherein the ADAR1 inhibiting agent reduces, or significantly reduces, ADAR1 Nano-luc reporter activity in cell lines and in human cancer stem cell assays. In alternative embodiments, provided are methods for inhibiting an RNA virus or a retrovirus, optionally a SARs-COV-2 virus, comprising lentiviral ADAR1 overexpression and in vivo administration, optionally intravenous (IV) administration, of a lentiviral ADAR1 transduced stem cell, optionally the stem cell is a cord blood CD34+ cell or a mesenchymal stromal cell.
Resumen de: MX2021008131A
The present disclosure provides expression constructs comprising a GLA transgene encoding the at least one α-Gal A protein for use in expressing α-Gal A proteins and preventing, inhibiting or treating Fabry disease or one or more symptoms associated with Fabry disease.
Resumen de: KR20250142178A
본 발명은 활성성분을 포함하는 균질하고 견고한 폴리머 복합체 나노입자(Polymer Complexes Nanoparticles, PMNP)와 자가유화 용액(Self-emulsifying solution, SES)로부터 자가유화 나노입자(Self-emulsifying nanoparticle, SENP) 및 비침습적 자가유화 나노입자 운반시스템(Self-emulsifying nanoparticle delivery system, SENPDS)을 제안하였다. 본 발명의 상기 SENPDS는 3중 다층 구조체로 생체 내에서 견고한 PMNP 함유 오일방울로 전환하여 자가소수성 반전 및 자가전하 반전을 하여 기존 SNEDDS(Self-nanoemulsifying drug delivery system)와 다른 생체장벽 회피 전략으로 향상된 생체이용률을 확인하였다. 본 발명은 SENP, SENPDS 및 이들의 제조 방법에 관한 것이다.
Resumen de: WO2024165949A1
The present invention relates to a method for the production of gold nanoparticles (AuNPs) coated with glutathione and Li+ ions, hereinafter designated as LiG-AuNPs, to a method for the preparation of aggregates of said nanoparticles and to the use of said nanoparticles, aggregates or compositions thereof which comprise them for therapeutic use. LiG-AuNPs then are an effective instrument in inhibiting GSK-3 and its downstream molecular targets, while keeping the lithium extracellular concentration levels below the systemic toxicity threshold (1.5 mEq/L), and exerting an antioxidant action by means of the glutathione present on their surface.
Resumen de: AU2024207086A1
A miRNA-mimic based therapeutic particle is disclosed herein. The particles comprise a synthetic miRNA or mimic of miR-187-3p encapsulated in a lipid nanoparticle (LNP) carrier or synthetic miR-193b-5p inhibitor encapsulated in a lipid carrier or their combination encapsulated in a lipid carrier. The lipid nanoparticle carrier is made up of at least four (4) types of lipids, in which the four (4) types of lipids include a) an ionizable cationic lipid selected to be positively charged in a formulation buffer (pH 4), which binds and protects the negatively charged miRNA, and facilitates endosomal escape, and is neutral in a storage buffer, b) a sterol in the structure of the lipid nanoparticle (LNP)., c) a structural helper lipid selected to contribute to lipid nanoparticle stability and/or enhances endosomal release, and d) a PEGylated-lipid selected such that it stabilizes the therapeutic particle and protects it from opsonization.
Resumen de: CN120717975A
本发明属于药物制剂技术领域，涉及一种二硫键桥联的杂环叔胺‑紫杉醇前药及其纳米粒的制备方法和应用。一种二硫键桥联的杂环叔胺‑紫杉醇前药，前药为式一所示杂环叔胺‑前药或其药学上可接受的盐，本发明二硫键桥联的杂环叔胺‑紫杉醇前药解决疏水药物溶解性差、改善疏水药物利用的表面活性剂容易引起的安全性问题，所述应用二硫键特异性响应释放增加药物选择性和安全性、利用杂环叔胺增加药物自组装能力、组装成纳米粒后通过EPR效应增加药物在肿瘤部位的蓄积、利用杂环叔胺结构具有pH响应的特点并在溶酶体中引起质子海绵效应以提高药物的细胞内递送效率；进而本发明前药及其自组装纳米粒。
Resumen de: CN120713849A
本发明公开了一种多糖修饰的锰‑没食子酸配合物及其制备和应用，属于金属多酚配合物和医药技术领域。本发明选用锰离子与没食子酸通过直接自组装来制备锰‑没食子酸的配合物，并通过逐层修饰技术引入聚醚表面活性剂和多糖(透明质酸)，聚醚表面活性剂和透明质酸包覆于配合物表面，最终形成了具有类芬顿活性、能够用于治疗肿瘤的多糖修饰的锰‑没食子酸配合物；其中，喜树碱与锰‑没食子酸的配合物协同发挥更强的治疗效果；聚醚表面活性剂的引入有助于促进组分溶解，还能提高稳定性，更容易透过细胞膜被细胞吸收；透明质酸的引入有助于提高生物相容性和对肿瘤细胞的靶向作用。
Resumen de: CN118873637A
The invention discloses a preparation method of an amyloid-like albumin coating modified Fe3O4 nanoparticle and application of the amyloid-like albumin coating modified Fe3O4 nanoparticle in anti-immune clearance, and relates to the technical field of nano-medicines. The preparation method comprises the following steps: S1, performing amyloid-like transformation on human albumin HSA to prepare an amyloid-like albumin ALH solution; and S2, modifying the amyloid-like albumin solution prepared in the step S1 on the surface of a Fe3O4 nano particle to prepare the nano particle ALH-Fe3O4 nano particle modified by the amyloid-like albumin coating. According to the preparation method of the Fe3O4 nanoparticles modified by the amyloid-like albumin coating and the application of the Fe3O4 nanoparticles modified by the amyloid-like albumin coating in anti-immune clearance, the albumin is subjected to amyloid-like transformation, so that the albumin is quickly self-assembled on the surfaces of the Fe3O4 nanoparticles to realize stable film formation, and meanwhile, the antiagonist performance of the albumin is maintained; the modification method is rapid in operation, wide in application range, free of organic solvents in the preparation process, environmentally friendly and suitable for large-scale commercial production.
Resumen de: CN120713860A
本发明涉及纳米光敏剂以及生物技术领域，尤其涉及一种PLGA封装GE11肽偶联亲水型酞菁纳米光敏剂及其制备方法和应用，包括：制备PLGA预聚物；制备ZnPcS光敏剂，将其磺酰氯化，得到ZnPcS-Cl活性端基；ZnPcS-Cl活性端基与GE11肽的胺基亲核取代，制备GE11-ZnPcS靶向偶联光敏剂；PLGA预聚物与GE11-ZnPcS光敏剂溶于油相体系，缓慢加入水相体系，在超声合成仪下，水包油乳化，得到PLGA@GE11-ZnPcS纳米光敏剂。本发明的PLGA@GE11-ZnPcS纳米光敏剂，利用680nm红光光照，应用于光动力杀灭人表皮鳞状皮肤癌细胞，具有光动力治疗效果。
Resumen de: CN120718133A
本发明公开了一种经过工程化改造的通用型铁蛋白载体疫苗及其应用。本发明公开了一种铁蛋白适配器、人铁蛋白重链突变体、通用型铁蛋白载体系统、抗原融合蛋白和铁蛋白载体疫苗，以及编码它们的核酸、含其的重组表达载体和转化体，以及它们的制备方法及应用。本发明首次明确了NCOA4(residue 484‑499)为FTH1的真实结合表位。设计出亲和力显著提高的Peptide及FTH1的突变体。基于本发明通用型铁蛋白载体系统的狂犬纳米颗粒疫苗，稳定性更高，能诱导更广泛、持久、强烈的免疫应答。2剂次免疫接种能够产生100％的保护效率，比市售的标准灭活疫苗BRP具备更佳的预防效果。
Resumen de: CN120713866A
本发明提供基于脂质体、外泌体与金属有机框架协同靶向治疗脂肪肝的纳米药物递送系统及其制备方法，涉及新型纳米材料制备技术领域，纳米药物递送系统包括：脂质体、间充质干细胞外泌体和金属有机框架纳米颗粒；脂质体为载体，包载具有缓释特性的金属有机框架纳米颗粒、间充质干细胞外泌体和miR‑204‑3p。通过整合脂质体、外泌体和金属有机框架的优势，实现对MASLD的协同治疗。该系统采用脂质体作为智能载体，包载具有缓释特性的MOF纳米颗粒和间充质干细胞外泌体，同时负载治疗性miR‑204‑3p。MOF材料兼具药物控释和活性氧清除功能，与外泌体及miRNA协同发挥抗氧化、抗炎和抗纤维化作用。该系统具有pH响应特性，能在MASLD病灶的酸性微环境中智能释放药物，实现肝脏靶向治疗。
Resumen de: CN120717973A
本发明提供一种通式A、通式B、通式C、通式D、通式E、通式F、通式B‑1、通式H、通式I、通式J、通式K或通式L所示的复合脂质化合物及其应用。该复合脂质化合物易于与核酸及蛋白等分子结合且易降解。本发明丰富了脂质化合物的种类，以其开发的递送载体对核酸及蛋白等多种分子的包封效率高，能够将药物在体内体外高效递送并高效表达，从而为核酸等药物递送提供了更多选择，对核酸类等药物的发展和应用具有重要的意义。
Resumen de: CN120713867A
本发明提供了一种微管蛋白破坏剂二聚体与铜死亡药物联用的纳米颗粒、其制备方法及用途，属于生物医药领域。本发明提供了一种微管蛋白破坏剂二聚体与铜死亡药物联用的纳米颗粒。所述微管蛋白破坏剂通过破坏细胞微管结构，诱导氧化应激及血流阻断，增强肿瘤细胞对氧化损伤的敏感性；铜死亡药物则促进铜离子积累，引发线粒体蛋白质聚集与功能障碍，最终诱导细胞死亡。两类药物联用，可产生显著协同抗肿瘤效应，显著提高治疗效率；同时，将这两类药物制备成纳米颗粒后用于抗肿瘤的选择性指数好，对细胞的毒副作用小。本发明具有广阔的临床转化前景和重要的社会经济价值。
Resumen de: CN120714037A
本发明涉及生物医药技术领域，公开了甲硫氨酸腺苷转移酶2A及其相关物质在制备抗衰产品中的应用。本发明发现甲硫氨酸腺苷转移酶2A(MAT2A)可以通过HMGCS1介导的泛醌合成，诱导线粒体代谢脆性，从而在调节细胞衰老中发挥之前未报道的代谢兼职作用。而在周细胞中特异性提高MAT2A基因表达量有助于提高细胞增殖活性、细胞线粒体呼吸水平、细胞的耗氧率、细胞总ATP水平和核形态标志物LaminB1的表达水平，同时降低衰老细胞百分比和衰老标志物P21的表达水平，提高甲硫氨酸腺苷转移酶2A表达的相关物质可用于制备抗衰药物。
Nº publicación: CN120714036A 30/09/2025
Solicitante:
中山大学附属第一医院
Resumen de: CN120714036A
本发明涉及生物医药技术领域，公开了甲硫氨酸腺苷转移酶2A及其相关物质在制备创面修复产品中的应用。本发明通过研究糖尿病创面中的代谢调控网络，发现在周细胞中下调的MAT2A表达与M1型巨噬细胞浸润呈显著负相关，并观察到伤口中周细胞的MAT2A特异性缺失会导致伤口愈合延迟、创面血流灌注减少，并伴有炎症巨噬细胞浸润的增加，而进一步采用负载saMAT2A的周细胞膜包被脂质纳米粒（PMCNPs）进行治疗后，能够显著增强创面的再生过程、减轻糖尿病创面中持续的炎症巨噬细胞浸润，并促进微循环的恢复，且安全性高，在促进创面修复方面具有很好的应用前景。
BOPI
Sede Electrónica
